Regenacy Pharmaceuticals
Michael Huang currently serves as Managing Partner of Taiwania Capital’s life science fund. Prior to joining Taiwania, Michael was the co-founder and CEO of NeuroVive Pharmaceutical Asia, Inc. (NVP Asia), a new drug development company focusing on the development of mitochondria-related diseases. During his tenure, NVP Asia had successfully signed out-licensing deals with global and Chinese pharmas. Michael has over 20 years of experience in investing and managing early to late-stage biotech and medical device companies in Greater China, Japan, European and North America regions. Michael received his MS degree in chemistry from University of Texas at Arlington and an MBA degree from Rice University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Regenacy Pharmaceuticals
Regenacy Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company’s selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders.